




Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L. Simpson¹ · Jonathan I. Silverberg² · Audrey Nosbaum³ · Kevin L. Winthrop¹ · Emma Guttman-Yassky⁴ · Karin M. Hoffmeister^{5,6} · Alexander Egeberg⁷ · Hernan Valdez⁸ · Min Zhang⁹ · Saleem A. Farooqui¹⁰ · William Romero¹¹ · Andrew J. Thorpe¹² · Ricardo Rojo¹³ · Susan Johnson¹² 

Published online: 13 October 2021
© Springer Nature Switzerland AG 2021

Correction to:

American Journal of Clinical Dermatology
(2021) 22:693–707

<https://doi.org/10.1007/s40257-021-00618-3>

The article was originally published electronically on SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new

corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40257-021-00618-3>.

✉ Susan Johnson
Susan.L.Johnson@pfizer.com

¹ Department of Dermatology, Oregon Health and Science University, Portland, OR, USA

² Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

³ Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France

⁴ Department of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁵ Versiti, Translational Glycomics Center, Blood Research Institute, Milwaukee, WI, USA

⁶ Departments of Biochemistry and Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

⁷ Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

⁸ Pfizer Inc., New York, NY, USA

⁹ Pfizer Inc., La Jolla, CA, USA

¹⁰ Pfizer R & D UK Ltd., Kent, UK

¹¹ Pfizer Ltd., Surrey, UK

¹² Pfizer Inc., Collegeville, PA, USA

¹³ Pfizer Inc., Groton, CT, USA